Online inquiry

IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ89MR)

This product GTTS-WQ89MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Breast Cancer, Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ89MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9512MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA J2898A
GTTS-WQ15374MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ15661MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ7211MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ3757MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ14440MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ1491MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ8627MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.